drugset / Trial / NCT05768360

A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide in Healthy Male Subjects

NCT05768360

Phase 1 Completed 6 enrolled AstraZeneca Parexel · collab
NaSequentialOpen-labelOther

Summary

This study will assess the effects of savolitinib on the pharmacokinetics (PK) of substrates of human transporters digoxin (P-gp), rosuvastatin (OATP1B1/3), metformin (OCT2, MATE1/2K), and furosemide (OAT1/3) in healthy male subjects, performed at a single clinical unit.

Timeline

Start
2023-04-25
Primary completion
2023-06-24
Completion
2023-06-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Digoxin Other / unclassified Oral
Subject Furosemide Other / unclassified Oral
Subject Metformin Small molecule Oral
Subject Rosuvastatin Small molecule Oral
Subject Savolitinib Small molecule Oral

Indications

No indication recorded.